Protective role of Nrf2 in the lungs against oxidative airway diseases;La voie Nrf 2 en pathologie resoiratoire

Medecine/Sciences

Volumn 27, Issue 11, 2011, Pages 966-972

  Boutten, Anne ^a,b   Goven, Delphine ^a   Artaud Macari, Élise ^a   Bonay, Marcel ^c,d  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NFE2L2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NRF2;

ANIMAL; BIOLOGICAL MODEL; CELL PROTECTION; DISEASE MODEL; GENETICS; HUMAN; LUNG; LUNG DISEASE; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CYTOPROTECTION; DISEASE MODELS, ANIMAL; HUMANS; LUNG; LUNG DISEASES; MODELS, BIOLOGICAL; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 83455211873     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20112711012     Document Type: Article

References (46)

1. Bonay M, Aubier M. Pollution atmosphérique et maladies respiratoires allergiques. Med Sci (Paris) 2007;23:187-92. (Pubitemid 46293865)
2. Yamamoto T, Sakaguchi N, Hachiya M, et al. Role of catalase in monocytic differentiation of U937 cells by TPA: hydrogen peroxide as a second messenger. Leukemia 2009;23:761-9.
3. Rangasamy T, Williams MA, Bauer S, et al. Nuclear erythroid 2 p45-related factor 2 inhibits the maturation of murine dendritic cells by ragweed extract. Am J Respir Cell Mot Biol 2010;43:276-85.
4. Walters DM, Cho HY, Kleeberger SR. Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2. Antioxid Redox Signal 2008;10:321-32.
5. Boutten A, Goven D, Boczkowski J, Bonay M. Oxidative stress targets in pulmonary emphysema: focus on the Nrf2 pathway. Expert Opin Ther Targets 2010;14:329-46.
6. Valko M, Leibfntz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84. (Pubitemid 44566469)
7. Leonarduzzi G, Sottero B, Poli G. Targeting tissue oxidative damage by means of cell signaling modulators: the antioxidant concept revisited. Pharmacol Ther 2010;128:336-74.
8. Sykiotis GP, Bohmann D. Stress-activated cap'n'collar transcription factors in aging and human disease. Sci Signal 2010;3. re3.
9. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keapl-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007;47:89-116.
10. Gong X, Kole L, Iskander K, Jaiswal AK. NRH: quinone oxidoreductase 2 and NAD (P) H: quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res 2007;67:5380-8. (Pubitemid 46997278)
11. Morse D, Choi AM. Heme oxygenase-1: from bench to bedside. Am J Respir Crit Care Med 2005;172:660-70. (Pubitemid 41324219)
12. Malhotra D, Portales-Casamar E, Singh A, et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChlP-Seq profiling and network analysis. Nucleic Acids Res 2010;38:5718-34.
13. Yoshida T, Tuder RM. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev 2007;87:1047-82. (Pubitemid 47084676)
14. Shaykhiev R, Krause A, Salit J, et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol 2009;183:2867-83.
15. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009;4:435-59.
16. Goven D, Boutten A, Lecon-Malas V, et al. Altered Nrf2/Keapl-Bachl equilibrium in pulmonary emphysema. Thorax 2008;63:916-924.
17. Goven D, Boutten A, Lecon-Malas V, et al. Prolonged cigarette smoke exposure decreases heme oxygenase-1 and alters Nrf2 and Bachl expression in human macrophages: roles of the MAP kinases ERK (l/2) and JNK. FCBS Lett 2009;583:3508-18.
18. Malhotra D, Thimmulappa R, Navas-Acien A, et al. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med 2008;178:592-604.
19. Malhotra D, Thimmulappa R, Vij N, et al. Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. Am J Respir Crit Care Med 2009;180:1196-207.
20. Siedlinski M, Postma DS, Boer JM, et al. Level and course of FEV1 in relation to polymorphisms in NFE2L2 and KEAP1 in the general population. Respir Res 2009;10:73.
21. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009;136:1364-70.
22. Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009;15:1077-81.
23. Braun S, Hanselmann C, Gassmann MG, et al. Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol 2002;22:5492-505. (Pubitemid 34755759)
24. Bakin AV, Stourman NV, Sekhar KR, et al. Smad3-ATF3 signaling mediates TGF-beta suppression of genes encoding Phase II detoxifying proteins. Free Radic Biol Med 2005;38:375-87. (Pubitemid 40075579)
25. Mazur W, Lindholm P, Vuorinen K, et al. Cell-specific elevation of NRF2 and sulfiredoxin-1 as markers of oxidative stress in the lungs of idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Apmis 2010;118:703-12.
26. Artaud-Macari E, Goven D, Brayer S, et al. Modulation of fibroblast phenotype in idiopathic pulmonary fibrosis: role of Nrf2. Am J Respir Erit Care Med 2011;183: A5989.
27. Marzec JM, Christie JD, Reddy SP, et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. Faseb J 2007;21:2237-46. (Pubitemid 47026458)
28. Kim SH, Choi GS, ye YM, et al. Toluene diisocyanate (TDl) regulates haem oxygenase-1/femtin expression: implications for toluene diisocyanateinduced asthma. Clin Cxp Immunol 2010;160:489-97.
29. Nichols DP, Ziady AG, Shank SL, et al. The tnterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease. Am J Physiol Lung Cell Mol Physiol 2009;297: L828-36.
30. Rene C, Lopez E, Claustres M, et al. NF-E2-related factor 2, a key inducer of antioxidant defenses, negatively regulates the CFTR transcription. Cell Mol Life Sci 2010;67:2297-309.
31. Ohta T, lijima K, Miyamoto M, et al. Loss of Keapl function activates Nrf 2 and provides advantages for lung cancer cell growth. Cancer Res 2008;68:1303-9. (Pubitemid 351346836)
32. Cho Hy, Reddy SP, Kleeberger SR. Nrf 2 defends the lung from oxidative stress. Antioxid Redox Signal 2006;8:76-87. (Pubitemid 43324533)
33. Boutten A, Goven D, Artaud-Macari E, et al. NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease. Trends Mol Med 2011;17:363-71.
34. Spira A, Beane JE, Shah V, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 2007;13:361-6. (Pubitemid 46376687)
35. Aoki Y, Hashimoto AH, Amanuma K, et al. Enhanced spontaneous and benzo (a) pyrene-induced mutations in the lung of Nrf2-deficient gpt delta mice. Cancer Res 2007;67:5643-8. (Pubitemid 46984995)
36. Martin-Montalvo A, Villalba JM, Novas P, de Cabo R. NRF2, cancer and calorie restriction. Oncogene 2010;30:505-20.
37. Shibota T, Ohta T, Tong Kl, et al. Cancer related mutations in NRF2 impair its recognition by Keopl-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 2008;105:13568-73.
38. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009;34:176-88.
39. Niso-Santano M, Gonzalez-Polo RA, Bravo-San Pedro JM, et al. Activation of apoptosis signalregulating kinase 1 is a key factor in paraquat-induced cell death: modulation by the Nrf2/Trx axis. Free Radic Biol Med 2010;48:1370-81.
40. Shah ZA, Li RC, Ahmad AS, et al. The flavanol (-)-epicatechin prevents stroke damage through the Nrf2/H01 pathway. J Cereb Blood Flow Metab 2010;30:1951-61.
41. Mann GE, Bonacasa B, Ishii T, Siow RC. Targeting the redox sensitive Nrf 2-Keapl defense pathway in cardiovascular disease, protection afforded by dietary isoflavones. Curr Opin Pharmacol 2009;9:139-45.
42. Yoon HY, Kang Nl, Lee HK, et al. Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem Pharmacol 2008;75:2214-23.
43. Hsu CL, Wu L, Tang GJ, et al. Ginkgo biloba extract confers protection from cigarette smoke extract-induced apoptosis in human lung endothelial cells: role of heme oxygenase-1. Pulm Pharmacol Ther 2009;22:286-96.
44. Yang L, Calingasan Ny, Thomas B, et al. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One 2009;4:e5757.
45. Ichikawa T, Li J, Meyer CJ, et al. Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes. PLoS One 2009;4:e8391.
46. Sussan TE, Rangasamy T, Blake DJ, et al. Targeting Nrf 2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci USA 2009;106:250-5.